Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epix MS-325 User Fee Date Extended

This article was originally published in The Pink Sheet Daily

Executive Summary

The user fee date for Epix' vascular imaging agent MS-325 is being extended to Jan. 15, the company said Oct. 4.

You may also be interested in...



Epix Pegs Vasovist Approval In Second Half 2007 Following Second “Approvable” Letter

FDA’s action letter for the vascular imaging agent requires an additional clinical trial and a re-read of images from previous trials.

Epix Pegs Vasovist Approval In Second Half 2007 Following Second “Approvable” Letter

FDA’s action letter for the vascular imaging agent requires an additional clinical trial and a re-read of images from previous trials.

Schering AG/Epix' Imaging Agent Requires Additional Clinical Studies, FDA Says

FDA requests further clinical studies for MS-325 (gadofosveset trisodium) to demonstrate efficacy, the "approvable" letter states. The outstanding questions relate to the non-contrast comparator scanning methods used in Phase III trials and the statistical treatment of uninterpretable baseline scans.

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel